Nicholas Stergis

NICHOLAS STERGIS is the co-Founder, Vice Chairman of the Board of Directors and
Chief Executive Officer of Adeona Pharmaceuticals, Inc. He previously served as
the company’s Chief Operating Officer from its founding during 2001 until
October 2006. From 2003 until 2007, Mr. Stergis was also a Founder and Vice
Chairman of Encode Pharmaceuticals, Inc., a drug development company, until its
acquisition by Raptor Pharmaceuticals, Inc., a publicly traded company. Mr.
Stergis was a co-Founder, Chief Operating Officer and Director of Developmental
Therapeutics, Inc., a cardiovascular drug development company, until its
acquisition in October 2003 by Titan Pharmaceuticals, Inc., a publicly traded
pharmaceutical company. Mr. Stergis was also a co-Founder and Managing Director
of Accredited Ventures Inc., a venture capital firm specializing in the
biotechnology and pharmaceutical industries. He was also Managing Director of
Accredited Equities, Inc., a FINRA member firm. Prior to co-founding Accredited
Ventures, he was the Interim Director of Corporate Development for Corporate
Technology Development, Inc. (CTD), a biopharmaceutical company based in Miami,
Florida, until its merger with DOR BioPharma, Inc., a publicly traded
biotechnology company. During his tenure at CTD, he was responsible for all
development tasks associated with the company’s lead product, orBec , which has
completed a pivotal Phase III clinical trial for an orphan indication. He was
also instrumental in CTD’s divestiture of important botulinum toxin intellectual
property to Allergan, Inc., a publicly traded specialty pharmaceutical
companies, as well as the divestiture of its European operations, Institute for
Drug Research, Ltd., to Ivax Corporation, a publicly traded pharmaceutical
company. Prior to joining CTD, Mr. Stergis was a Technology Associate at
Paramount Capital, a New York-based private equity, venture capital, investment
banking and asset management group specializing in the biotechnology and
pharmaceutical industries. There, he participated in the startup, acquisition
and financing of various biotechnology companies. Mr. Stergis received his MS in
Biology from New York University as well as a BS in Biology from the University
at Albany, State University of New York.